AllianceBernstein
KLRS

AllianceBernstein’s Kalaris Therapeutics KLRS Stock Holding History

AllianceBernstein’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,801
Closed -$48.6K – 3311
2024
Q1 		$48.6K Hold
2,801
– – ﹤0.01% 3091
2023
Q4 		$43.8K Sell
2,801
-272
-9% -$10.7K ﹤0.01% 3138
2023
Q3 		$152K Buy
3,073
+451
+17% +$30.7K ﹤0.01% 3013
2023
Q2 		$205K Buy
2,622
+687
+36% +$65.3K ﹤0.01% 2975
2023
Q1 		$175K Buy
1,935
+239
+14% +$30.4K ﹤0.01% 2942
2022
Q4 		$200K Buy
1,696
+457
+37% +$77.5K ﹤0.01% 3009
2022
Q3 		$225K Buy
1,239
+74
+6% +$11.5K ﹤0.01% 2977
2022
Q2 		$105K Buy
1,165
+195
+20% +$20.4K ﹤0.01% 3120
2022
Q1 		$151K Hold
970
– – ﹤0.01% 3051
2021
Q4 		$289K Sell
970
-1,484
-60% -$688K ﹤0.01% 2953
2021
Q3 		$1.41M Sell
2,454
-55,552
-96% -$25.7M ﹤0.01% 2356
2021
Q2 		$26.3M Buy
58,006
+10,189
+21% +$5.26M 0.01% 827
2021
Q1 		$25.7M Buy
47,817
+3,399
+8% +$2.86M 0.01% 844
2020
Q4 		$39.3M Buy
44,418
+2,734
+7% +$2.1M 0.02% 652
2020
Q3 		$26.4M Buy
+41,684
New +$28.5M 0.01% 717

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein's KLRS Position: Q2 2024 in Review

AllianceBernstein sold out of Kalaris Therapeutics (KLRS) in Q2 2024, closing a stake of 2,801 shares — an estimated $48.6K sold.

AllianceBernstein first reported a position in KLRS in Q3 2020 and held it in 15 quarters. The position peaked at $39.3M in Q4 2020. 71 funds tracked by Wall St. Rank hold KLRS as of Q2 2024.

  • AllianceBernstein reported no remaining Kalaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • AllianceBernstein sold 2,801 Kalaris Therapeutics shares in Q2 2024, an estimated $48.6K.
  • AllianceBernstein first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 15 quarters.
  • AllianceBernstein's Kalaris Therapeutics position peaked at $39.3M in Q4 2020.
  • 71 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2024.

Based on AllianceBernstein's 13F filing for Q2 2024, filed 14 Aug 2024.